CeriBell, Inc. Common Stock

Day range

$25.86 – $26.42

Open

$26.20

Prev close

$26.35

Volume

267.64K

Market cap

$1.02B

Shares out

38.84M

P/E

—

P/S

9.34

P/B

8.64

P/FCF

—

ROE

-62.9%

ROA

-47.3%

Debt/Equity

0.17

Div yield

0.00%

As of Nov 13, 2026

• Quarterly earningsNov 3, 2026

  On November 3, 2026, CeriBell, Inc. issued a press release announcing its financial results for the fiscal quarter ended September 30, 2026.

• Director appointmentJul 30, 2026

  Immediately following the foregoing rebalancing, and effective July 28, 2026, the Board increased the authorized size of the Board from seven to nine directors and elected Sharon L. O'Keefe and Thomas A. West to fill the newly created directorships, each to serve as a Class I director until his or her successor is duly elected and qualified, or until his or her earlier resignation or removal. Ms. O'Keefe has also been appointed to the Compensation Committee of the Board, and Mr. West has also been appointed to the Audit Committee of the Board.

• Regulatory decisionJan 5, 2026

  On January 5, 2026, CeriBell, Inc. (Ceribell) issued a press release announcing that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for Ceribell's Large Vessel Occlusion (LVO) stroke detection and monitoring solution.

• Director departureJan 2, 2026

  On December 30, 2025, Lucian Iancovici notified the Board of Directors (the "Board") of CeriBell, Inc. (the "Company") of his resignation from the Board and from his positions as Chair of the Nominating and Corporate Governance Committee and as a member of the Compensation Committee, effective as of December 31, 2025.

• Lease agreementDec 12, 2025

  On December 11, 2025, the Company and WTA Pastoria II LLC (the "360 Lessor") entered into the First Amendment, effective December 8, 2025 (the "360 Amendment"), to the Lease dated July 13, 2021... Pursuant to the 360 Amendment, the Company and the 360 Lessor agreed to extend the term of the 360 Lease through January 31, 2028, with a monthly rent of $74,147.00.

Days to cover

3.5

Short interest

1.96M

Avg volume

550.61K

As of Oct 30, 2026 · reported to FINRA twice monthly.

• CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
  neutralZacks Investment Research· Nov 3, 2026
• Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
  positiveZacks Investment Research· Nov 3, 2026
• Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe
  positiveGlobeNewswire Inc.· Jul 29, 2026
• Ceribell Receives FDA 510(k) Clearance for Use of ClarityⓇ Algorithm for Neonates
  positiveGlobeNewswire Inc.· Nov 24, 2025
• Medtech Leader Erica Rogers Joins Ceribell Board of Directors
  positiveGlobeNewswire Inc.· Sep 22, 2025